Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
Cytokinetics (Nasdaq: CYTK) has announced its participation in two major investor conferences this May. The company will engage in fireside chats at:
- The Citizens Life Sciences Conference on May 7, 2025, at 10:00 AM ET at the New York Hilton Midtown Hotel
- The 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 8:30 AM ET at the InterContinental New York Barclay Hotel
Both fireside chats will be accessible via live webcasts through the Investors & Media section of Cytokinetics' website. Recordings will remain available for 90 days after the events.
Cytokinetics (CYTK) has announced it will release its first quarter 2025 financial results on May 6, 2025, at 4:00 PM Eastern Time. Following the earnings release, the company's senior management will host a conference call at 4:30 PM Eastern Time to discuss the financial performance and provide business updates.
The conference call will be accessible through a simultaneous webcast from the Investors & Media section of Cytokinetics' website. Participants can also join via telephone by pre-registering through a provided link. A replay of the webcast will remain available on the company's website for six months.
Cytokinetics (CYTK) has announced new inducement grants for 13 employees who joined the company in March and April 2025. The compensation package includes:
- Stock options to purchase 60,670 shares of common stock at $38.56 per share (closing price on April 15, 2025)
- 40,888 restricted stock units (RSUs)
The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3), while stock options vest over 4 years (25% after first year, remaining monthly over 36 months). The stock options have a 10-year term. These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.
Cytokinetics (Nasdaq: CYTK) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Monday, April 7, 2025, at 2:15 PM Eastern Time.
Investors and interested parties can access the live webcast through the Investors & Media section of Cytokinetics' website. The webcast recording will remain available on the company's website for 90 days after the event concludes.
Cytokinetics (NASDAQ: CYTK) has launched EARTH-HCM, an innovative online public health education tool focusing on hypertrophic cardiomyopathy (HCM). This interactive platform analyzes real-world, de-identified claims data from over 65,000 pharmacies, 1,500 hospitals, 800 outpatient facilities, and 80,000 physician practices across the U.S.
The tool, developed in collaboration with leading academic institutions, visualizes population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization, and costs in HCM. EARTH-HCM aims to serve multiple stakeholders, including patients, clinicians, researchers, policy makers, payors, and advocacy groups.
The platform utilizes Symphony Health's Integrated Dataverse prescription claims database, covering HCM patients diagnosed between 2016 and 2023. Regular updates are planned, with future expansion to include global data.
Cytokinetics (CYTK) has announced new equity compensation grants as inducement awards to 13 new employees who joined in February and March 2025. The grants include:
- 58,631 stock options at $44.36 per share (closing price on March 14, 2025)
- 38,068 restricted stock units (RSUs)
- 3,381 performance stock units (PSUs)
The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3). Stock options will vest over 4 years (25% after year 1, remaining monthly over 36 months) with a 10-year term. PSUs are tied to two performance goals, with 50% of shares earned upon certification of each goal, followed by a two-stage vesting schedule.
Cytokinetics (CYTK) announced five presentations about aficamten, their investigational cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), at the upcoming American College of Cardiology Annual Scientific Session.
Key findings include:
- Drug metabolism study showed aficamten is eliminated through multiple CYP pathways: CYP2C9 (50%), CYP3A (26%), CYP2D6 (21%), and CYP2C19 (3%)
- Analysis of combination therapy with disopyramide showed good tolerability without enhanced LVOT gradient reduction compared to aficamten alone
- 72-week treatment data demonstrated significant improvements in cardiac structure and function, including reduced left ventricular mass index, wall thickness, and mitral regurgitation
- Placebo analysis revealed approximately one-third of KCCQ-OSS improvements were due to placebo effect
- Race/ethnicity study in non-obstructive HCM showed Black patients had higher rates of adverse cardiovascular outcomes compared to white patients
Cytokinetics (Nasdaq: CYTK) has announced its participation in three major investor conferences this March 2025. The company's leadership will be present at:
- The Leerink Global Biopharma Conference on March 10, featuring a fireside chat with CEO Robert I. Blum and CCO Andrew Callos at 11:20 AM ET in Miami Beach
- The Jefferies Biotech on the Beach Summit on March 11, with management conducting one-on-one meetings
- The Barclays 27th Annual Global Healthcare Conference on March 12, including a fireside chat at 1:30 PM ET
All events will take place in Miami Beach, FL. Live webcasts of the fireside chats will be available on the Cytokinetics website's Investors & Media section, with replays archived for 90 days.
Cytokinetics (NASDAQ: CYTK) reported Q4 and full year 2024 financial results, highlighting significant progress in its cardiac muscle programs. The company's lead drug candidate aficamten is under regulatory review in the US, Europe, and China, with a PDUFA date of September 26, 2025.
Key financial metrics include:
- Cash position of ~$1.2 billion as of December 31, 2024
- Q4 2024 revenues of $16.9 million vs $1.7 million in Q4 2023
- Full year 2024 revenues of $18.5 million vs $7.5 million in 2023
- Q4 2024 net loss of $150.0 million ($1.26 per share)
- Full year 2024 net loss of $589.5 million ($5.26 per share)
The company entered collaborations with Bayer for aficamten commercialization in Japan and noted Sanofi's acquisition of rights for Greater China. Topline results from the MAPLE-HCM trial are expected in Q2 2025.
Cytokinetics (CYTK) has granted equity-based compensation to 6 new employees who joined in February 2025. The package includes 23,337 stock options at an exercise price of $46.16 per share and 15,153 restricted stock units (RSUs).
The RSUs will vest over 3 years with a 40-40-20 schedule: 40% after year one, 40% after year two, and 20% after year three. The stock options will vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next 36 months. The options have a 10-year term.
These grants were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and are subject to the company's Amended and Restated 2004 Equity Incentive Plan.